HK1044708B - Oncolytic vesicular stomatitis virus - Google Patents
Oncolytic vesicular stomatitis virus Download PDFInfo
- Publication number
- HK1044708B HK1044708B HK02105578.7A HK02105578A HK1044708B HK 1044708 B HK1044708 B HK 1044708B HK 02105578 A HK02105578 A HK 02105578A HK 1044708 B HK1044708 B HK 1044708B
- Authority
- HK
- Hong Kong
- Prior art keywords
- vsv
- virus
- cells
- use according
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39787399A | 1999-09-17 | 1999-09-17 | |
| US19990397873 | 1999-09-17 | ||
| PCT/US2000/025510 WO2001019380A2 (en) | 1999-09-17 | 2000-09-18 | Oncolytic virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1044708A1 HK1044708A1 (en) | 2002-11-01 |
| HK1044708B true HK1044708B (en) | 2006-10-27 |
Family
ID=23573018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK02105578.7A HK1044708B (en) | 1999-09-17 | 2000-09-18 | Oncolytic vesicular stomatitis virus |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1218019B1 (https=) |
| JP (1) | JP5060694B2 (https=) |
| CN (1) | CN1289098C (https=) |
| AT (2) | ATE319460T1 (https=) |
| AU (1) | AU782402B2 (https=) |
| CA (1) | CA2386920C (https=) |
| DE (2) | DE60026554T2 (https=) |
| ES (2) | ES2260057T3 (https=) |
| HK (1) | HK1044708B (https=) |
| IL (2) | IL148621A0 (https=) |
| MX (1) | MXPA02002772A (https=) |
| NZ (4) | NZ517573A (https=) |
| WO (1) | WO2001019380A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| HK1052950B (en) | 2000-06-26 | 2005-06-24 | Wellstat Biologics Corporation | Purging of cells using viruses |
| EP1385466B1 (en) | 2001-05-11 | 2011-03-09 | Wellstat Biologics Corporation | Oncolytic virus therapy |
| AU2008201293B2 (en) * | 2001-07-11 | 2011-08-18 | University Of Miami | Recombinant VSV for the treatment of tumor cells |
| US20030044386A1 (en) * | 2001-07-11 | 2003-03-06 | Barber Glen N. | Recombinant VSV for the treatment of tumor cells |
| JP2004099584A (ja) | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US7731974B2 (en) * | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| DE602004018284D1 (de) * | 2003-03-27 | 2009-01-22 | Ottawa Health Research Inst | Mutante vesicular stomatitis viren und deren verwendungen |
| US8012747B2 (en) | 2004-06-01 | 2011-09-06 | San Diego State University Foundation | Expression system |
| CN101065144B (zh) * | 2004-08-20 | 2012-06-13 | 溶瘤病毒有限公司 | 治疗血液癌症的方法和组合物 |
| CA2577692C (en) | 2004-08-20 | 2014-05-06 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| CA2663034C (en) * | 2006-09-15 | 2016-05-03 | Ottawa Health Research Institute | Oncolytic rhabdovirus |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| JP2011507523A (ja) * | 2007-12-21 | 2011-03-10 | ワイス・エルエルシー | 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法 |
| JP2012500229A (ja) | 2008-08-21 | 2012-01-05 | オタワ ホスピタル リサーチ インスティチュート | 遺伝子操作された相乗的腫瘍溶解性ウイルス共生 |
| DE102008050860A1 (de) * | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
| US9707285B2 (en) | 2009-03-16 | 2017-07-18 | Turnstone Limited Partnership | Vaccination methods |
| CA2836117C (en) * | 2009-12-10 | 2017-08-15 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| US9428736B2 (en) | 2010-09-02 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| CA2872045A1 (en) | 2011-06-08 | 2012-12-13 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
| WO2013050048A2 (en) | 2011-10-07 | 2013-04-11 | Skau Aps | Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses |
| CA2901501C (en) | 2013-02-21 | 2023-03-07 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Vaccine composition |
| DK2983706T3 (en) | 2013-04-10 | 2021-06-14 | Univ Aarhus | Use of Immune Suppressive Domains as Medicaments |
| CA2915045A1 (en) | 2013-06-14 | 2014-12-18 | Turnstone Limited Partnership | Compositions and methods for enhancing virus replication |
| EP2826856B9 (en) * | 2013-07-16 | 2016-05-04 | Sia Latima | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof |
| EP3172562B1 (en) | 2014-07-21 | 2019-03-13 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
| CN105233285B (zh) * | 2015-09-06 | 2018-10-12 | 广州威溶特医药科技有限公司 | Epac直接或间接激动剂与溶瘤病毒的联合应用 |
| WO2018213412A1 (en) | 2017-05-19 | 2018-11-22 | Georgia State University Research Foundation, Inc. | Recombinant oncolytic virus |
| US10610583B2 (en) | 2017-08-31 | 2020-04-07 | Regents Of The University Of Minnesota | Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus |
| ES2991089T3 (es) | 2017-09-22 | 2024-12-02 | Centre Nat Rech Scient | Glicoproteína mutada del virus de la estomatitis vesicular |
| CN110499297B (zh) * | 2019-08-29 | 2021-07-09 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| CN116724110A (zh) * | 2020-08-14 | 2023-09-08 | 上海行深生物科技有限公司 | 重组溶瘤病毒及其构建方法和用途 |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| AU2022227021A1 (en) | 2021-02-26 | 2023-09-21 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| AU2024353243A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1118403B (de) | 1960-01-27 | 1961-11-30 | Hoechst Ag | Verfahren zur Gewinnung von antitumorwirksamen Sporen |
| GB1069144A (en) | 1963-07-10 | 1967-05-17 | Merck & Co Inc | Method for the treatment of malignant tumors |
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| CA2132328C (en) | 1992-03-24 | 2000-10-31 | Laszlo K. Csatary | Vaccine containing live virus for therapy of viral diseases and malignancies |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE69722608T2 (de) | 1996-01-25 | 2004-04-29 | The University Court Of The University Of Glasgow, Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| PT1012244E (pt) * | 1997-07-11 | 2007-08-21 | Univ Yale | ''rabdovírus com revestimentos remanipulados'' |
| IL135507A0 (en) * | 1997-10-09 | 2001-05-20 | Pro Virus Inc | Treatment of neoplasms with viruses |
| NZ505312A (en) * | 1997-12-22 | 2003-01-31 | Univ Tennesse Res Corp | Recombinant Vesicular Stomatitis virus comprising a heterologous F protein (Paramyxovirus strain SV5) and CD4 antireceptor protein |
| CA2323067A1 (en) * | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Producer cells for replication selective viruses in the treatment of malignancy |
| KR100637937B1 (ko) | 1998-06-12 | 2006-10-23 | 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 | 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스 |
| JP2003530301A (ja) * | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
-
2000
- 2000-09-18 NZ NZ517573A patent/NZ517573A/en not_active IP Right Cessation
- 2000-09-18 DE DE60026554T patent/DE60026554T2/de not_active Expired - Lifetime
- 2000-09-18 NZ NZ534306A patent/NZ534306A/en not_active IP Right Cessation
- 2000-09-18 MX MXPA02002772A patent/MXPA02002772A/es active IP Right Grant
- 2000-09-18 NZ NZ523805A patent/NZ523805A/en not_active IP Right Cessation
- 2000-09-18 IL IL14862100A patent/IL148621A0/xx unknown
- 2000-09-18 CA CA2386920A patent/CA2386920C/en not_active Expired - Fee Related
- 2000-09-18 DE DE60041210T patent/DE60041210D1/de not_active Expired - Lifetime
- 2000-09-18 AT AT00965106T patent/ATE319460T1/de active
- 2000-09-18 HK HK02105578.7A patent/HK1044708B/en not_active IP Right Cessation
- 2000-09-18 JP JP2001523012A patent/JP5060694B2/ja not_active Expired - Fee Related
- 2000-09-18 WO PCT/US2000/025510 patent/WO2001019380A2/en not_active Ceased
- 2000-09-18 ES ES00965106T patent/ES2260057T3/es not_active Expired - Lifetime
- 2000-09-18 AU AU75882/00A patent/AU782402B2/en not_active Ceased
- 2000-09-18 ES ES05025974T patent/ES2320239T3/es not_active Expired - Lifetime
- 2000-09-18 EP EP00965106A patent/EP1218019B1/en not_active Expired - Lifetime
- 2000-09-18 AT AT05025974T patent/ATE418341T1/de active
- 2000-09-18 CN CNB008158983A patent/CN1289098C/zh not_active Expired - Fee Related
- 2000-09-18 NZ NZ534307A patent/NZ534307A/en not_active IP Right Cessation
- 2000-09-18 EP EP05025974A patent/EP1716858B9/en not_active Expired - Lifetime
-
2002
- 2002-03-11 IL IL148621A patent/IL148621A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1716858A2 (en) | 2006-11-02 |
| EP1218019B1 (en) | 2006-03-08 |
| EP1716858B9 (en) | 2009-08-12 |
| HK1044708A1 (en) | 2002-11-01 |
| CA2386920A1 (en) | 2001-03-22 |
| IL148621A0 (en) | 2002-09-12 |
| EP1218019A2 (en) | 2002-07-03 |
| NZ534306A (en) | 2005-12-23 |
| EP1716858B1 (en) | 2008-12-24 |
| MXPA02002772A (es) | 2004-04-02 |
| NZ534307A (en) | 2005-07-29 |
| IL148621A (en) | 2010-02-17 |
| DE60026554T2 (de) | 2006-09-28 |
| CN1496268A (zh) | 2004-05-12 |
| EP1716858A3 (en) | 2007-08-15 |
| DE60026554D1 (de) | 2006-05-04 |
| NZ523805A (en) | 2004-09-24 |
| CN1289098C (zh) | 2006-12-13 |
| AU782402B2 (en) | 2005-07-28 |
| CA2386920C (en) | 2012-01-24 |
| ATE319460T1 (de) | 2006-03-15 |
| ES2320239T3 (es) | 2009-05-20 |
| WO2001019380A2 (en) | 2001-03-22 |
| HK1092713A1 (en) | 2007-02-16 |
| ES2260057T3 (es) | 2006-11-01 |
| JP2004525855A (ja) | 2004-08-26 |
| AU7588200A (en) | 2001-04-17 |
| ATE418341T1 (de) | 2009-01-15 |
| NZ517573A (en) | 2004-02-27 |
| DE60041210D1 (de) | 2009-02-05 |
| JP5060694B2 (ja) | 2012-10-31 |
| WO2001019380A3 (en) | 2001-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1218019B1 (en) | Oncolytic vesicular stomatitis virus | |
| US8147822B1 (en) | Oncolytic virus | |
| EP1032269B1 (en) | Treatment of neoplasms with interferon-sensitive, clonal viruses | |
| CA2370187C (en) | Treatment of neoplasms with viruses | |
| US20030044384A1 (en) | Treatment of neoplasms with viruses | |
| US7470426B1 (en) | Treatment of neoplasms with viruses | |
| HK1092713B (en) | Oncolytic virus | |
| AU2005237176C1 (en) | Treatment of neoplasms with viruses | |
| Cary | Assessing an M mutant vesicular stomatitis virus for the treatment of glioblastoma multiforme by determining apoptotic mechanisms and antiviral response | |
| HK1112815A (en) | Treatment of neoplasms with viruses | |
| HK1028935B (en) | Treatment of neoplasms with interferon-sensitive, clonal viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20110918 |